DIA
17.10.2018 08:02:04 CEST | Business Wire | Press release
DIA , founded as the Drug Information Association, announced three keynote speakers for the upcoming DIA Europe 2019 annual meeting: Dave deBronkart, ‘e-Patient Dave’; Hans Lehrach, Director at the Max Planck Institute for Molecular Genetics; and Kristel Van der Elst, CEO, The Global Foresight Group. The diversity of experience brought by these three leaders is reflective of the meeting mission to ensure industry, payers, patients, and regulators all have an equal voice in the debates advancing regulatory science and access to healthcare.
These keynote speakers will join 300 speakers in more than 80 sessions, across seven thought leadership streams to drive collaborative answers in medicines development and access to healthcare. Highlights from sessions include Guido Rasi, Executive Director, EMA, will present first look strategies for 2021-2025 during the European Regulatory Town Hall and Niklas Hedberg, Chair EUnetHTA Executive Board, will feature case studies of Real World Evidence in Market Access . All sessions and speaker details can be viewed in the recently launched and continuously updated Searchable Programme . The Programme Highlights provides an overview of the key successes from DIA Europe 2018 and the direction conversations will take in 2019. Cross-functional dialogues will address cutting-edge topics such as the Evolution of Science and Policy , Modern Clinical Research , Access to Medicines , and Digital Disruptors .
The annual meeting theme of, “Join Us at the Crossroads of Healthcare”, continues to emphasize the multi-stakeholder, outcome-driven dialogue that occurs at the DIA Europe annual meeting. “Stakeholders come from across the world to hear about how Europe is approaching some of the most important issues of the day for regulatory science, for patients, and for how healthcare is going to develop not only here in Europe, but clearly what contributions we have to make to the broader global debates,” as Virginia Acha, Executive Director, Global Regulatory Policy, MSD and member of the DIA Europe Steering Committee, shared in a recent video interview .
Critically important for all development and access stakeholders is understanding current policies as well as future pathways for regulatory science. DIA Europe 2019 brings together representatives from over 35 regulatory, HTA, and patient advocacy agencies throughout the globe, including European Medicines Agency (EMA), Medicines and Healthcare products Regulatory Agency (MHRA), Federal Institute for Drugs and Medical Devices (BfArM), Pharmaceuticals and Medical Devices Agency (PMDA), and the Austrian Medicines and Medical Devices Agency (AGES).
“The DIA Europe 2018 annual meeting set a high bar both in terms of attendance and level of engagement. We look forward to building upon that momentum of confronting the tough challenges facing drug development professionals. While DIA’s history has its roots in bringing together regulatory professionals, we’ve evolved to address the interconnectedness of all functions and facilitate discussions across the entire drug development spectrum – from discovery to marketed use. 2019 will be no different,” details Thomas Bols, Senior Vice President and Managing Director for DIA Europe, Middle East, and Africa (EMEA).
To learn more and register for DIA Europe 2019 visit, DIAglobal.org/Europe2019 . For live updates, follow and join the conversation on Twitter, @DIA_Europe using the hashtag #DIAEurope2019.
About DIA
DIA (founded as the Drug Information Association) is a global association that mobilizes life science professionals from across all areas of expertise to engage with patients, peers, and thought leaders in a neutral environment on the issues of today and the possibilities for tomorrow. As a member-driven, volunteer organization, professionals from more than 80 countries have affected healthcare outcomes, by engaging with DIA through an unparalleled network, educational offerings, and professional development opportunities.
DIA is based in Washington, DC (US) with regional offices representing the Americas (Horsham, PA, US); Europe, the Middle East, and Africa, (Basel, Switzerland); and Asia (Beijing and Shanghai, China; Mumbai, India; and Tokyo, Japan).
For more information, visit DIAglobal.org or connect with DIA on Twitter , LinkedIn , Facebook , and Instagram .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181016005167/en/
Contact:
DIA Jacqueline Zeller, Marketing Jacqueline.Zeller@DIAglobal.org
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 01:00:00 CEST | Press release
Phase 1 study has demonstrated pharmacokinetics (PK) equivalence between SB27 and KeytrudaPhase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sour
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 00:00:00 CEST | Press release
Megaport DDoS Protection removes the trade-off between security, performance, and cost, offering rapid enterprise-grade mitigation. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing s
IFF Reports First Quarter 2026 Results5.5.2026 22:23:00 CEST | Press release
Delivered solid top and bottom line Q1 resultsProgressing disciplined sale process for Food Ingredients businessReaffirms Full Year 2026 Financial Guidance IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks t
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 22:06:00 CEST | Press release
Strong FY 2026 Demonstrates Strategy and Operating Principles Are Delivering SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in
Sentinel Midstream Advances Texas GulfLink Deepwater Port5.5.2026 22:00:00 CEST | Press release
Marks Historic Milestone for U.S. Energy Export Infrastructure under the U.S.-Japan Trade Deal Sentinel Midstream LLC (Sentinel) today announced the commencement of its Texas GulfLink deepwater port (Texas GulfLink or the Project), marking a significant milestone enabled by funding received pursuant to the U.S.—Japan Trade Agreement. The project advances in coordination with the U.S. Department of Commerce and the Government of Japan and reflects the shared commitment to strengthening global energy security and expanding U.S. export infrastructure. Sentinel will lead the development of Texas GulfLink, overseeing construction, commercial operations, and long-term management of the terminal. Funding provided under the U.S.—Japan Trade Agreement, pursuant to Executive Order 14345 signed on September 4, 2025, underscores continued international confidence in U.S. energy infrastructure and supports the expansion of American crude oil exports to global markets. Upon this commencement, Texas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom